Novel Technologies News for February 2011

Novel Technologies News Archive

Waters increases the number of its speakers at its upcoming International Symposium in Manchester Waters increases the number of its speakers at its upcoming International Symposium in Manchester

The "6th International MS Symposium" is the latest in an occasional series of scientific meetings initiated (by Micromass) in 1998. Today these meetings are sponsored by Waters MS Technologies. The format is that of a legitimate scientific meeting, open to all, that typically attracts Ca 150+ delegates.

RNID ‘TRIH’ TO ACCELERATE CURES FOR HEARING LOSS AND TINNITUS THROUGH PIONEERING NEW INITIATIVE RNID ‘TRIH’ TO ACCELERATE CURES FOR HEARING LOSS AND TINNITUS THROUGH PIONEERING NEW INITIATIVE

New medicines to prevent and treat hearing loss or tinnitus could be available within 10 years, if a bold new initiative by RNID succeeds in bringing scientists, pharmaceutical companies, funding bodies and private investors together to accelerate clinical trials.

Advances in Cell Based Screening Technologies 2011 Advances in Cell Based Screening Technologies 2011

ELRIG (European Laboratory Robotics Interest Group) are hosting a free conference on the 15th March 2011 at Hinxton Hall, Cambridge UK on the topic of “Advances in Cell-Based Screening Technologies.With technological developments advancing at a seemly ever-increasing pace, methods of monitoring biological activity that a decade ago wouldn’t look out of place on Star Trek are beginning to filter into the lab.How are these being used, what can they tell us and what are the limitations? At this conference you will hear talks on the latest cutting edge detection technologies and biological techniques transitioning into screening labs. How are they faring and what might you using 10 years from now?

AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme AstraZeneca and Pfizer Join Cancer Research UK’s Stratified Medicine Programme

CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.Cancer Research UK’s pioneering “Stratified Medicine Programme”* will also promote research into new targeted treatments by building a database of genetic information about tumours, treatments and survival rates that will enable researchers to design more effective cancer treatments in future.